Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center
出版年份 2017 全文链接
标题
Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center
作者
关键词
Sodium-glucose co-transporter 2 inhibitors (SGLT2i), Long-term treatment, Real-world evidence
出版物
Diabetology & Metabolic Syndrome
Volume 9, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-12-01
DOI
10.1186/s13098-017-0297-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Diabetes: SGLT2 inhibitors and diabetic ketoacidosis — a growing concern
- (2017) Guillermo E. Umpierrez Nature Reviews Endocrinology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors in the real world: too good to be true?
- (2017) David Fitchett Lancet Diabetes & Endocrinology
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
- (2017) Andrew McGovern et al. Diabetes Therapy
- Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
- (2017) Andrew McGovern et al. Diabetes Therapy
- The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition
- (2017) Subodh Verma et al. JAMA Cardiology
- SGLT2 Inhibitors: Benefit/Risk Balance
- (2016) André J. Scheen Current Diabetes Reports
- Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial
- (2016) Eirik Søfteland et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates
- (2016) Mathew John et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials
- (2016) Atsunori Kashiwagi et al. Journal of Diabetes Investigation
- SGLT2 Inhibitors: The Latest “New Kids on the Block”!
- (2015) William T. Cefalu et al. DIABETES CARE
- Where Does Combination Therapy With an SGLT2 Inhibitor Plus a DPP-4 Inhibitor Fit in the Management of Type 2 Diabetes?
- (2015) Muhammad Abdul-Ghani DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Comparison of HbA1c, blood pressure, and cholesterol (ABC) control in type 2 diabetes attending general medical clinics and specialist diabetes clinics in Thailand
- (2015) Sokha Sieng et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events
- (2015) Daisuke Yabe et al. Expert Opinion On Drug Safety
- Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years
- (2015) Xiang-Yang Liu et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet
- (2015) Tomohide Hayami et al. Journal of Diabetes Investigation
- Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
- (2015) Wataru Ogawa et al. Journal of Diabetes Investigation
- Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
- (2014) A.J. Scheen et al. DIABETES & METABOLISM
- Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
- (2014) Julio Rosenstock et al. DIABETES CARE
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
- (2014) Yoshihito Fujita et al. Journal of Diabetes Investigation
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Achievement of Goals in U.S. Diabetes Care, 1999–2010
- (2013) Mohammed K. Ali et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials
- (2013) Asres Berhan et al. BMC Endocrine Disorders
- SGLT inhibitors in management of diabetes
- (2013) Abd A Tahrani et al. Lancet Diabetes & Endocrinology
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search